Leukemia - search results

By rewiring the inner workings of the cancer cells and inhibiting a certain enzyme, researchers were able to prime acute myeloid leukemia (AML) cells for sensitivity to treatment in the laboratory and help reverse the resistance of leukemia cells to tyrosine kinase inhibitors (TKI).

Researchers have created a new vaccine against SARS-CoV-2—CoVac-1—that induces a T cell immune response in a high proportion of patients with leukemia and lymphoma.

Malformed early lymphocyte precursor cells are common in treatment-resistant infant B-cell acute lymphoblastic leukemia and have distinct biological markers that could be targeted in future treatments, shows U.K. research.

To help overcome relapse of T-cell acute lymphoblastic leukemia (T-ALL), researchers from Princess Máxima Center for pediatric oncology in Utrecht, the Netherlands, collaborated with Amsterdam UMC to find new ways to tackle the disease. The researchers demonstrated in mice that blocking a protein chain reaction makes childhood leukemia cells more sensitive to an existing targeted treatment.

The phosphatase protein SCP4 seems to be essential for acute myeloid leukemia cell survival and researchers hope this could lead to the discovery of new targeted drugs for this aggressive cancer.

An international team has mapped how the human T-cell lymphotropic virus type 1 causes a rare form of leukemia called adult T-cell leukemia/lymphoma. The new findings offer clues on how to stop the infection from inducing cancer.

In pediatric and young adult patients with acute lymphoblastic leukemia treated with tisagenlecleucel (Kymriah), DNA sequencing-based detection of residual disease identified all patients who would eventually relapse, and was more accurate than flow cytometry.

Targeting the IGF2BP3 protein using CRISPR-Cas9 could be a good strategy for human patients with aggressive leukemia characterized by chromosomal rearrangements in the MLL gene, according to preclinical research.

Researchers indicated that stem cell memory T cells appear to be critical for both destroying the cancer at the outset, and for long-term immune surveillance. The team suggests that exploiting this quality could improve the design and performance of CAR T therapies.

Cancer-causing leukemic stem cells are present in small numbers in patients and are hard to identify using conventional techniques. A single-cell omics approach can identify mutational status and gene expression in stem cells from acute myeloid leukemia patients and locate disease-causing cells for later targeting.